MoonLake Immunotherapeutics MLTX Invested capital
Discontinued — last reported Q1 '26
Invested capital at other companies
Other financials
Where this comes from
Calculated from MoonLake Immunotherapeutics’s reported figures.
The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about MoonLake Immunotherapeutics's invested capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is MoonLake Immunotherapeutics's invested capital?
- MoonLake Immunotherapeutics (MLTX) reported invested capital of $56.34M in Q1 2026.
- How has MoonLake Immunotherapeutics's invested capital changed year-over-year?
- MoonLake Immunotherapeutics's invested capital decreased by 73.4% year-over-year, from $211.52M to $56.34M.
- What is the long-term trend for MoonLake Immunotherapeutics's invested capital?
- Over 4 years (2021 to 2025), MoonLake Immunotherapeutics's invested capital has grown at a 81.1% compound annual growth rate (CAGR), from -$4.25M to $45.67M.
- What does invested capital mean?
- Total debt plus shareholders' equity minus cash, at the quarter end. The capital actually put to work in the operating business — the denominator of return on invested capital (ROIC).